Oppenheimer Asset Management Inc. Sells 58,073 Shares of Haleon plc (NYSE:HLN)

Oppenheimer Asset Management Inc. reduced its holdings in Haleon plc (NYSE:HLN) by 7.0% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 767,602 shares of the company’s stock after selling 58,073 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Haleon were worth $8,121,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the business. Clearbridge Investments LLC raised its position in shares of Haleon by 44.6% during the first quarter. Clearbridge Investments LLC now owns 38,446,978 shares of the company’s stock valued at $326,415,000 after buying an additional 11,865,076 shares during the last quarter. Sculptor Capital LP raised its holdings in Haleon by 67.8% in the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after acquiring an additional 3,592,000 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Haleon by 95.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock valued at $16,143,000 after acquiring an additional 954,622 shares in the last quarter. Raymond James & Associates lifted its position in shares of Haleon by 14.7% in the 2nd quarter. Raymond James & Associates now owns 4,019,978 shares of the company’s stock worth $33,205,000 after acquiring an additional 515,651 shares during the period. Finally, First Eagle Investment Management LLC grew its holdings in shares of Haleon by 36.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 1,862,056 shares of the company’s stock worth $15,381,000 after purchasing an additional 501,035 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Berenberg Bank started coverage on Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating for the company. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley lifted their target price on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. Finally, The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.95.

Haleon Stock Performance

Shares of NYSE:HLN opened at $9.30 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The business’s fifty day moving average price is $10.12 and its two-hundred day moving average price is $9.33. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The stock has a market capitalization of $42.08 billion, a price-to-earnings ratio of 27.34, a price-to-earnings-growth ratio of 2.80 and a beta of 0.30.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.